Tsakos Energy Navigation Limited
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Tsakos Energy Navigation Limited (TEN) is a global maritime company dedicated to the worldwide ocean transport of crude oil and refined petroleum products. The firm delivers vital shipping and logisti...
Latest News
4 days ago · seekingalpha.com
Tsakos Energy Navigation: The Preferred Might Be A Better Pick Than The CommonTsakos Energy Navigation Limited delivers strong results, but common holder cash returns remain underwhelming despite robust earnings. I rate TEN common shares Hold and Series F preferred Buy, favoring the nearly 9% fixed yield and substantial dividend coverage of Series F. Recent $150M repurchase authorization and a $1 common dividend for January 2027 are positive, but capital returns still lag peers.
7 days ago · globenewswire.com
TEN, Ltd. Announces Common Shares Dividend and Share Repurchase Authorization100% increase on first semi-annual common shares dividend $150 million common and preferred shares repurchase authorization ATHENS, Greece, Oct. 26, 2026 (GLOBE NEWSWIRE) -- TEN, Ltd. (NYSE: TEN) (the “Company”) following the conclusion of the Company's Strategy Meeting, the Company today announced that in January 2027 it will distribute its first semi-annual dividend of $1.00 per share to common shareholders with payment and record dates to be announced in due course.
8 days ago · gurufocus.com
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancerRYBREVANT FASPRO⢠(amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced he
13 days ago · gurufocus.com
Sun Pharma Announces UNLOXCYT® (cosibelimab-ipdl) Has Received a Category 2A Preferred Designation in the Updated NCCN Guidelines for Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) PatienSun Pharma Announces UNLOXCYTÂ (cosibelimab-ipdl) Has Received a Category 2A Preferred Designation in the Updated NCCN Guidelines for Locally Advanced Cutaneou
26 days ago · businesswire.com
TEN Hires Versatile Marketing Leader Daniel Incandela as Chief Marketing OfficerDUBLIN, Ohio--(BUSINESS WIRE)--TEN, the largest full-service trailer lessor in North America, has appointed Daniel Incandela as Chief Marketing Officer.
28 days ago · globenewswire.com
TEN Ltd. Declares Dividend on its Series F Cumulative Redeemable Perpetual Preferred SharesATHENS, Greece, Oct. 05, 2026 (GLOBE NEWSWIRE) -- TEN Ltd. (NYSE: TEN) (“TEN” or the “Company”), a leading diversified tanker and LNG operator, today announced that its Board of Directors declared the regular quarterly cash dividend of approximately $0.59375 per share for its Series F Cumulative Redeemable Perpetual Preferred Shares (the “Series F Preferred Shares”; NYSE: TENPRF).
1 month ago · marketbeat.com
Tsakos Energy Navigation Highlights $3.6B Contract Backlog, Tanker Fleet ExpansionTsakos Energy Navigation NYSE: TEN outlined its tanker-market strategy, fleet expansion plans and recent earnings performance during the Lytham Partners Fall 2026 Investor Conference, with Advisor to the Board and head of investor relations Mike Kimble emphasizing the company's long-term contracts with major oil companies.
1 month ago · globenewswire.com
TEN, Ltd. Continues Its Fleet Renewal and Reports Sale of Panamax TankerDynamic Fleet Growth on Track Five New-Technology Panamaxes on Order Tanker Market Fundamentals Remain Strong ATHENS, Greece, Sept. 28, 2026 (GLOBE NEWSWIRE) -- TEN, Ltd.
2 months ago · gurufocus.com
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026RYBREVANT FASPRO⢠(amivantamab and hyaluronidase-lpuj) plus LAZCLUZE (lazertinib) with prophylactic strategies shows low rates of treatment-related events a
2 months ago · gurufocus.com
TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trialUpdated exploratory results from the ADAURA Phase III trial showed AstraZeneca's TAGRISSOÂ (osimertinib) demonstrated a sustained, clinically meaningful overal
Analyst Summary
Add to Watchlist
Select watchlists to add or remove TEN